| Hib4
|
6 wks |
4 weeks
if 1st dose given at age <12 mos
8 weeks (as final dose)
if 1st dose given at age 12–14 mos
No further doses needed
if 1st dose given at age ≥15 mos |
4 weeks4
if current age <12 mos
8 weeks (as final dose)4
if current age ≥12 mos and 1st dose given at age <12 mos and
2nd dose given at age <15 mos
No further doses needed
if previous dose given at age ≥15 mos |
8 weeks (as final dose)
This dose only necessary for ages 12 mos–59 mos who received 3 doses
at age <12 mos |
|
| PCV5
|
6 wks |
4 weeks
if 1st dose given at age <12 mos
8 weeks (as final dose for healthy children)
if 1st dose given at age ≥12 mos or current age 24–59 mos
No further doses needed
for healthy children if 1st dose given at age ≥24 mos |
4 weeks
if current age <12 mos
8 weeks (as final dose for healthy children)
if current age ≥12 mos
No further doses needed
for healthy children if previous dose given at age ≥24 mos |
8 weeks (as final dose)
This dose only necessary for ages 12 mos–5 yrs who received 3 doses
at age <12 mos or for high-risk children who received 3 doses at any age |
|